ライフサイエンスコーパス: lipoglycan

1 e terminal mannosyl oligosaccharides of this lipoglycan.

2 ion receptors other than TLR2 as sensors for lipoglycans.

3 d in various functions associated with these lipoglycans.

4 f its major thiol and of essential cell wall lipoglycans.

5 but not succinyl ester, affected binding of lipoglycans.

6 14(+) T cell receptor (TCR) specific for the lipoglycan alpha-galactosylceramide (alpha-GalCer), whic

7 /- and LTbeta-/- mice did not respond to the lipoglycan alpha-galactosylceramide, which is presented

8 Release of lipoglycans and lipoproteins from infected macrophages w

9 imary means by which M. tuberculosis exports lipoglycans and lipoproteins to impair effector function

10 ding phospholipids, glycerolipids, bacterial lipoglycans and plant glycolipids.

11 Despite the immunogenicity of microbial lipoglycans and their promiscuous binding to CD1d, no pa

12 localized in organelles that may be sites of lipoglycan antigen loading.

13 mannose receptor in antigen presentation of lipoglycan antigens and evidence that the mannose recept

14 lex, and the phosphatidyl-myo-inositol-based lipoglycans are key features of the mycobacterial cell w

15 These lipoglycans are transferred to T cells to inhibit T cell

16 study enhances our understanding of complex lipoglycan biosynthesis in Corynebacterineae and sheds f

17 slow growth phenotype and a global defect in lipoglycan biosynthesis.

18 M. tuberculosis lipoproteins and lipoglycans block phagosome maturation, inhibit class II

19 Presentation of this lipoglycan by CD1b requires antigen uptake via the manno

20 y uncharacterized, albeit the recognition of lipoglycans by Toll-like receptor 2 (TLR2) appears to be

21 ulation of CD4(+) T cells by M. tuberculosis lipoglycans conveyed by BVs that are produced by M. tube

22 cules has demonstrated that human CD1b and a lipoglycan from mycobacteria that CD1b presents colocali

23 cytometry and Western blot demonstrated that lipoglycans from M. tuberculosis-derived bacterial vesic

24 e mycobacterial glycosylphosphatidylinositol lipoglycan/glycolipid class.

25 ycolipids and membrane anchors for cell wall lipoglycans in the Corynebacteria.

26 e T cell recognition of microbial lipids and lipoglycans in the presence of CD1b-expressing antigen-p

27 ed Corynebacterium glutamicum as a source of lipoglycan intermediates for host interaction studies.

28 iNOS and NO(.) by a mycobacterial cell wall lipoglycan known as mannose-capped lipoarabinomannan (Ma

29 of iNOS and NO* by a mycobacterial cell wall lipoglycan known as mannose-capped lipoarabinomannan (Ma

30 d presentation pathway for the mycobacterial lipoglycan lipoarabinomannan (LAM) in monocyte-derived a

31 ycobacteria by binding to the mannose-capped lipoglycan lipoarabinomannan.

32 annosyl units of the M. tuberculosis surface lipoglycan, lipoarabinomannan (LAM), from the Erdman str

33 ve recently determined that a major capsular lipoglycan, lipoarabinomannan (LAM), from the Erdman str

34 erns, such as the phosphatidylinositol-based lipoglycans, lipomannan (LM) and lipoarabinomannan (LAM)

35 The mycobacterial lipoglycans, lipomannan (LM) and lipoarabinomannan (LAM)

36 other containing M. tuberculosis molecules (lipoglycans, lipoproteins).

37 Biochemical analysis of the lipoglycans obtained in the presence (wild type) or abse

38 he genus-specific phosphatidylinositol-based lipoglycans of mycobacteria.

39 ipoarabinomannan are prominent phospholipids/lipoglycans of Mycobacterium sp. believed to play import

40 lipoarabinomannan, which are key glycolipids/lipoglycans of the mycobacterial cell envelope.

41 lipoarabinomannan, which are key glycolipids/lipoglycans of the mycobacterial cell envelope.

42 Another important mannosylated lipoglycan on the M. tuberculosis surface is lipomannan

43 displays a wide array of complex lipids and lipoglycans on its cell surface.

44 lf-ligands, which might be either autologous lipoglycans or peptides.

45 l LM, further highlighting the complexity of lipoglycan pathways of Corynebacterineae.

46 AM) is a high molecular weight, heterogenous lipoglycan present in abundant quantities in Mycobacteri

47 is a structurally heterogeneous amphipathic lipoglycan present in Mycobacterium spp. and other actin

48 tive bacteria) produce LTAs, rather than the lipoglycans previously assumed to be typical of this tax

49 te immunity through recognition of bacterial lipoglycans, primarily LPS.

50 rall, the data are consistent with a mode of lipoglycan recognition similar to that proposed for glyc

51 s been shown to present microbial lipids and lipoglycans such as mycolic acids and lipoarabinomannan

52 s inhibited by M. tuberculosis cell envelope lipoglycans, such as lipoarabinomannan and lipomannan, b

53 eous suppressor strain was isolated in which lipoglycan synthesis in the DeltaNCgl1054 mutant was par

54 lipoarabinomannan (LAM), a key mycobacterial lipoglycan that has been implicated in numerous immunore

55 involved in the biosynthesis of mannosylated lipoglycans that participate in the association of mycob

56 nomannan and lipomannan, but a mechanism for lipoglycans to traffic from M. tuberculosis within infec

57 veal a complex structure, named T. vaginalis lipoglycan (TvLG), that differs markedly from Leishmania

58 annosides, long presumed precursors of these lipoglycans, was retained.

59 Lipopolysaccharide (LPS) is a unique lipoglycan, with two major physiological roles: 1), as a